As seen in most human cancers, loss of CDKN2A transcript expression was generally exclusive of RB1 loss, while three tumors had both TP53 variants and RB1 loss and one tumor had MDM2 overexpression with RB1 loss25. This evidence concerns the gene TP53 and cancer.